Dependence of reported purity on the analytical method
How much does a reported chromatographic purity figure vary with the method used to obtain it?
§1Abstract
§1.1Review question
How much does a reported chromatographic purity figure vary with the method used to obtain it?
§1.2PICO frame
Table 1. The registered PICO frame. Any change made after protocol registration is recorded in the amendment log at §5 and is identified there as post hoc.
| Element | As registered |
|---|---|
| Population | Synthetic peptides analysed by reverse-phase chromatography. |
| Intervention | Variation in gradient, column chemistry, detection wavelength and integration practice. |
| Comparator | A single stated reference method. |
| Outcomes | Reported area-percentage purity for the same material. |
§1.3Method in brief
A review of analytical and quality evidence for a compound or class as supplied, rather than of clinical effect. The protocol was registered with the Institute's secretariat before the search was executed. The search was run on 6 August 2025 across 8 sources and is reproduced in full at §2. Screening, extraction and certainty assessment were performed independently by two members of the secretariat with disagreement resolved by a third.[1,2]
§1.4Conclusion
High certainty evidence, again analytical rather than clinical, establishes that the same material can yield materially different area-percentage purity figures under different gradients, at different detection wavelengths, and under different integration practice, and that a shallow gradient resolving a close-eluting variant will report a lower purity than a steep gradient that co-elutes it. A purity figure reported without its method is therefore not comparable with any other purity figure. This is the single strongest reason the Institute treats the naming of the method as a critical certificate field.
The conclusion rests on 24 contributing studies, listed with their extracted data at §3 and summarised outcome by outcome at §4.
§1.5Limitations
§1.6Consultation
This review was released for public comment before ratification. Draft synthesis: Dependence of reported purity on the analytical method received 4 submissions. Amendments arising are recorded in the amendment log and are traceable to a numbered submission.
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- United States Pharmacopeial Convention. General Chapter ⟨1225⟩ Validation of Compendial Procedures. United States Pharmacopeia — National Formulary (USP–NF) 2024;USP 2024 Issue 1. identifier not held by the Institute
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q2(R2) Validation of Analytical Procedures. ICH Harmonised Guideline 2023;Step 4 version, 1 November 2023. identifier not held by the Institute
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.